## Background: Anti-dna topoisomerase i (anti-topo i) antibodies have been broadly studied in systemic sclerosis (ssc). the use of different native and molecularly cloned antigens has shown a predominant igg response, and a variable frequency of positive igm and iga tests. we report herein the sero
Anti—topoisomerase i antibodies in silica-associated systemic sclerosis. A model for autoimmunity
✍ Scribed by Neil John Mchugh; Jean Whyte; Georgina Harvey; Uwe F. Haustein
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 984 KB
- Volume
- 37
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.
Methods. Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).
Results. Nine of the 14 patients with silicaassociated SSc had anti-top0 I antibodies. All anti-top0 I antibodies in the patients with silica-associated SSc and in 14 anti-top0 I-positive patients with idiopathic SSc were directed at an active site of top0 I, or at least sterically inhibited its function. One patient with silicaassociated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to RoISS-A and LdSS-B autoantigens.
Conclusion. Anti-top0 I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-top0 I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.
📜 SIMILAR VOLUMES
## Abstract ## Objective To determine any associations of the __PTPN22__ R620W single‐nucleotide polymorphism (SNP) with systemic sclerosis (SSc) or with anticentromere antibody (ACA)–positive or anti–topoisomerase I (anti–topo I) antibody–positive SSc, in a case–control study of US white, black,
## Abstract ## Objective To describe the clinical and laboratory features and natural history of the disease in systemic sclerosis (SSc; scleroderma) patients with anti–topoisomerase I (anti–topo I) antibody who have different skin thickness progression rates (STPRs). ## Methods SSc patients (n